Pfizer and BioNTech announce agreement with the United Kingdom for 30 million doses of mRNA-based vaccine candidate against SARS-CoV-2

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses.

from Breaking World Pharma News https://ift.tt/30MmQk8